Press Releases
Page 13 • 8 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
Vitestro's Autonomous Robotic Phlebotomy Device Shows Promising Results in Multicenter Clinical Trial
Vitestro publishes peer-reviewed multicenter ADOPT trial results for Aletta® Autonomous Robotic Phlebotomy Device, demonstrating safety and performance.
Grace Therapeutics GTx-104 Phase 3 STRIVE-ON Trial Results Accepted for AAN 2026 Presentation
Grace Therapeutics announces STRIVE-ON Phase 3 safety trial results for GTx-104 injectable nimodipine accepted for AAN 2026 presentation.
MENA Medical Device Regulatory Training Course Launches May 2026 to Address Growing Market Demand
New MENA medical device regulatory training course scheduled for May 18-19, 2026, helps companies navigate approval processes in growing Middle East markets.
CMO/CDMO Market to Reach $5.46 Billion by 2035 as Biologics Manufacturing Outsourcing Accelerates
The global CMO/CDMO market will grow from $4.02 billion to $5.46 billion by 2035, driven by biologics outsourcing and specialized manufacturing demand.
New Clinical Trial Monitoring Course Addresses Rising GCP Compliance Issues in Biopharmaceutical Industry
Online GCP compliance course launches June 2026 to address increasing regulatory inspection findings in clinical trial monitoring across biopharma and CROs.
New GCP Inspections Training Course Addresses ICH GCP E6(R3) and EU CTR Compliance for Pharmaceutical Companies
ResearchAndMarkets.com announces comprehensive GCP inspections training covering EU, FDA, and MHRA expectations under updated ICH GCP E6(R3) guidelines.
Vabysmo Market Report 2026: Roche's Eye Drug Shows Strong Growth Through 2035 Amid Rising Retinal Disorder Cases
New market research reveals Vabysmo's projected growth through 2035, driven by advances in retinal disorder diagnosis and expanding ophthalmology clinics.
GlycoNex GNX1021 Gets PMDA Approval for First-in-Human Phase 1 Trial in Gastrointestinal Cancers
GlycoNex receives PMDA approval to begin first-in-human Phase 1 trial of GNX1021 antibody-drug conjugate for advanced gastrointestinal cancers in Japan.